Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYPTNASDAQ:KEQUNASDAQ:LABNYSE:SENS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYPTEyePoint Pharmaceuticals$5.68+1.4%$5.82$3.91▼$13.99$390.85M1.58815,934 shs368,862 shsKEQUKewaunee Scientific$35.60-3.4%$36.38$30.33▼$71.33$101.64M0.4724,060 shs2,932 shsLABStandard BioTools$0.92-3.4%$1.12$0.92▼$2.65$350.04M1.82.14 million shs2.59 million shsSENSSenseonics$0.50-3.9%$0.64$0.25▼$1.40$330.18M1.056.68 million shs5.66 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYPTEyePoint Pharmaceuticals0.00%-7.34%-13.15%-7.64%-50.48%KEQUKewaunee Scientific0.00%-4.58%+3.91%-35.91%-13.13%LABStandard BioTools0.00%-14.67%-25.07%-29.11%-64.42%SENSSenseonics0.00%-4.77%-33.80%-47.49%+5.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYPTEyePoint Pharmaceuticals2.0996 of 5 stars3.52.00.00.03.41.70.0KEQUKewaunee Scientific1.7936 of 5 stars0.03.00.80.02.72.51.3LABStandard BioTools2.0736 of 5 stars3.30.00.00.02.34.20.6SENSSenseonics2.0803 of 5 stars3.80.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYPTEyePoint Pharmaceuticals 3.00Buy$25.38346.74% UpsideKEQUKewaunee Scientific 0.00N/AN/AN/ALABStandard BioTools 2.50Moderate Buy$2.50171.27% UpsideSENSSenseonics 3.50Strong Buy$2.00296.28% UpsideCurrent Analyst Ratings BreakdownLatest KEQU, EYPT, LAB, and SENS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025EYPTEyePoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.005/8/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $27.004/10/2025SENSSenseonicsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$2.004/9/2025SENSSenseonicsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/6/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.003/6/2025EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/5/2025SENSSenseonicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.00 ➝ $2.002/27/2025LABStandard BioToolsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Sector Weight(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYPTEyePoint Pharmaceuticals$56.04M6.97N/AN/A$5.66 per share1.00KEQUKewaunee Scientific$220.03M0.46$0.79 per share45.30$13.60 per share2.62LABStandard BioTools$169.69M2.06N/AN/A($1.85) per share-0.50SENSSenseonics$23.68M13.94N/AN/A$0.07 per share7.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYPTEyePoint Pharmaceuticals-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)KEQUKewaunee Scientific$18.75M$5.915.64∞N/A9.39%25.83%10.75%6/25/2025 (Estimated)LABStandard BioTools-$74.66M-$0.35N/AN/AN/A-79.92%-27.05%-15.52%7/30/2025 (Estimated)SENSSenseonics-$60.39M-$0.11N/AN/AN/A-362.30%-842.25%-67.99%N/ALatest KEQU, EYPT, LAB, and SENS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025EYPTEyePoint Pharmaceuticals-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million3/12/2025Q3 2025KEQUKewaunee ScientificN/A$1.09N/A$0.45N/A$67.17 million3/5/2025Q4 2024EYPTEyePoint Pharmaceuticals-$0.54-$0.64-$0.10-$0.64$11.02 million$11.60 million3/3/2025Q4 2024SENSSenseonics-$0.03-$0.12-$0.09N/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYPTEyePoint PharmaceuticalsN/AN/AN/AN/AN/AKEQUKewaunee Scientific$0.762.13%N/A12.86%N/ALABStandard BioToolsN/AN/AN/AN/AN/ASENSSenseonicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYPTEyePoint PharmaceuticalsN/A5.505.45KEQUKewaunee Scientific0.452.642.13LABStandard BioToolsN/A3.763.41SENSSenseonics59.172.472.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYPTEyePoint Pharmaceuticals99.41%KEQUKewaunee Scientific32.69%LABStandard BioTools53.74%SENSSenseonics12.36%Insider OwnershipCompanyInsider OwnershipEYPTEyePoint Pharmaceuticals4.74%KEQUKewaunee Scientific14.20%LABStandard BioTools23.16%SENSSenseonics4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYPTEyePoint Pharmaceuticals12068.81 million65.02 millionOptionableKEQUKewaunee Scientific8902.86 million2.46 millionNot OptionableLABStandard BioTools620379.82 million174.59 millionOptionableSENSSenseonics90654.22 million573.90 millionN/AKEQU, EYPT, LAB, and SENS HeadlinesRecent News About These CompaniesSenseonics Holdings, Inc. Secures $57.5 Million in Public Offering and $20.3 Million from Private Placement with Abbott LaboratoriesMay 21, 2025 | quiverquant.comSenseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private PlacementMay 21, 2025 | globenewswire.comRevisiting Senseonics After 4 Years: Still A Big Investment OpportunityMay 21, 2025 | seekingalpha.comJane Street Group LLC Has $3.20 Million Holdings in Senseonics Holdings, Inc. (NYSE:SENS)May 16, 2025 | marketbeat.comSenseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private PlacementMay 15, 2025 | globenewswire.comSenseonics opens $50M public offering, $25M private placement with AbbottMay 15, 2025 | drugdeliverybusiness.comSenseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private PlacementMay 15, 2025 | globenewswire.comSenseonics (NYSE:SENS) Raised to "Sell" at StockNews.comMay 15, 2025 | marketbeat.comSenseonics Holdings, Inc. (AMEX:SENS) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSenseonics Holdings, Inc. Reports First Quarter Financial ResultsMay 9, 2025 | finance.yahoo.comSenseonics posts Q2 sales beat, submits 365-day CGM for CE markMay 9, 2025 | drugdeliverybusiness.comSenseonics targets $34M-$38M revenue in 2025 with Eversense 365 expansionMay 9, 2025 | msn.comSenseonics Holdings, Inc. (SENS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comSenseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comRenaissance Technologies LLC Makes New Investment in Senseonics Holdings, Inc. (NYSE:SENS)May 4, 2025 | marketbeat.comSenseonics (NYSE:SENS) Trading Up 6.3% - Here's What HappenedMay 1, 2025 | marketbeat.comSequel Med Tech and Senseonics Partner to Launch twiist™ AID System Compatible with Eversense® 365 CGMApril 30, 2025 | nasdaq.comSenseonics, Sequel partner to use 1-year CGM in automated insulin dosing systemApril 30, 2025 | medtechdive.comFirst Light Asset Management LLC Invests $3.37 Million in Senseonics Holdings, Inc. (NYSE:SENS)April 30, 2025 | marketbeat.comSequel Med Tech, Senseonics to integrate year-long CGM into automated insulin delivery systemApril 29, 2025 | drugdeliverybusiness.comSequel Med Tech to link Senseonics’ 365-day CGM with upcoming twiist insulin pumpApril 29, 2025 | fiercebiotech.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsBy Ryan Hasson | May 5, 2025View Rocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsOklo Reaches Critical Mass, Atomic Upside Still AvailableBy Thomas Hughes | May 14, 2025View Oklo Reaches Critical Mass, Atomic Upside Still AvailableRocket Lab: Earnings Miss But Neutron Momentum HoldsBy Ryan Hasson | May 12, 2025View Rocket Lab: Earnings Miss But Neutron Momentum HoldsHims & Hers Stock Soars on Novo Nordisk CollaborationBy Gabriel Osorio-Mazilli | April 30, 2025View Hims & Hers Stock Soars on Novo Nordisk CollaborationRetail Investors Are Betting Big on Rocket Lab—Should You Too?By Ryan Hasson | May 16, 2025View Retail Investors Are Betting Big on Rocket Lab—Should You Too?KEQU, EYPT, LAB, and SENS Company DescriptionsEyePoint Pharmaceuticals NASDAQ:EYPT$5.68 +0.08 (+1.43%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.60 -0.08 (-1.41%) As of 05/23/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Kewaunee Scientific NASDAQ:KEQU$35.60 -1.27 (-3.44%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$36.15 +0.55 (+1.54%) As of 05/23/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.Standard BioTools NASDAQ:LAB$0.92 -0.03 (-3.45%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.96 +0.04 (+4.17%) As of 05/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Senseonics NYSE:SENS$0.50 -0.02 (-3.87%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.52 +0.01 (+2.04%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
